Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.…
Crescent Biopharma: Q3 Earnings Snapshot
Crescent Biopharma (NASDAQ: CBIO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 80 employees.
The shares were at 13.00 USD on 20 November 2026, down 1.0% over 52 weeks. Its 52-week range is 8.720 USD to 27.41 USD: the price is 52.6% below the high and 49.1% above the low.
Its market capitalisation is 543.21M USD.
Crescent Biopharma reports return on equity of -75.8%.
It holds more cash than debt, a net cash position of 286.90M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 32.33 USD is 148.7% above the current price.